# Sparrow Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sparrow-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Portland, US
- Website: www.sparrowpharma.com
- Total disclosed funding: $63M
- Latest round: Series B (Jun 20, 2025)
- Investors on record: 5

## About

Based in Oregon, US, and founded in 2013, Sparrow Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded by Dr. David Katz and is backed by investors including OrbiMed Advisors, RiverVest Ventures, US Venture Partners, and other unspecified investors. In June 2025, Sparrow Pharmaceuticals, Inc. raised USD 61.84 million in series B funding co-led by new investors Forbion and RA Capital Management, with participation from returning investors OrbiMed Advisors, RiverVest Ventures Partners, and US Venture Partners.

Sparrow Pharmaceuticals provide treatment options for serious disorders of hypercortisolism, autoimmune and inflammatory conditions. The company also focuses on drug candidates such as SPI-62 and SPI-62 + prednisolone.

Sparrow Pharmaceuticals plans to advance its targeted therapy for type 2 diabetes.

## Funding rounds

- Series B, Jun 20, 2025, $62M — OrbiMed Advisors, US Venture Partners, RiverVest Ventures Partners, Forbion, RA Capital Management
- Series A, Dec 31, 2020, $1.1M — OrbiMed Advisors, US Venture Partners, RiverVest Ventures Partners

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series A, Series B
- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series A, Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B